Survodutide

Survodutide (BI 456906) is a dual agonist targeting both the GLP-1 receptor and the glucagon receptor, developed jointly by Boehringer Ingelheim and Zealand Pharma. Unlike tirzepatide, which combines GIP and GLP-1 receptor agonism, survodutide pairs GLP-1 with glucagon receptor agonism. This distinct combination leverages glucagon's ability to increase energy expenditure and promote hepatic fat mobilization alongside GLP-1's appetite-suppressing and insulin-sensitizing effects.

The inclusion of glucagon receptor agonism is particularly relevant for liver fat reduction and NASH treatment. Glucagon promotes hepatic lipid oxidation and reduces hepatic lipogenesis, making dual GLP-1/glucagon agonists especially promising for liver disease. Phase 2 clinical data have shown that survodutide produces significant reductions in liver fat content, with a substantial proportion of NASH patients achieving histological improvement.

For weight management, phase 2 trial results showed survodutide produced dose-dependent weight loss of up to approximately 19% over 46 weeks at the highest tested dose. While not quite matching tirzepatide or retatrutide's top-line numbers, these results represent clinically meaningful weight loss and confirm the viability of the GLP-1/glucagon dual agonist approach.

Survodutide represents one of several next-generation approaches in the rapidly evolving obesity and metabolic disease space. Its differentiation from tirzepatide (GIP/GLP-1) and retatrutide (GIP/GLP-1/glucagon) through a distinct receptor combination offers a different balance of metabolic effects. The NASH indication may prove to be its strongest clinical niche, as glucagon's hepatic effects provide a clear mechanistic rationale for liver fat reduction that GIP agonism does not share.